OncoMed Pharma (OMED) Tops Q1 EPS by 2c

OncoMed Pharma (NASDAQ: OMED) reported Q1 EPS of ($0.61), $0.02 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $6.2 million versus the consensus estimate of $6.97 million.

2017 Financial Guidance OncoMed anticipates 2017 full-year cash expenses will be approximately $90 million, including the impact of one-time severance-related charges in the range of approximately $2.6 million to approximately $3.1 million related to our previously announced workforce reduction. Based on the current plan, OncoMed anticipates that its current cash balance is sufficient to fund pipeline development and company operations through the third quarter of 2019, before considering potential opt-in milestones under our Celgene collaboration.

For earnings history and earnings-related data on OncoMed Pharma (OMED) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• KULR Technology Group (KULR) Misses Q2 EPS by 39c
• Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Tops Q2 EPS by 24c